After adjusting for baseline and demographic characteristics, we found that the risk of nonadherence to antipsychotic treatment was lowest among older patients, those without concomitant psychiatric diagnoses (substance abuse or other psychoses) or selected concomitant medications, and those receiving long-acting second-generation medications or oral first- and second-generation medications. Furthermore, our findings confirm that nonadherence is associated with a greater risk of hospitalization. These findings will be useful to health plan administrators, formulary decision makers, and physicians who treat patients with schizophrenic disorders.
This study was sponsored by Ortho-McNeil Janssen Scientific Affairs, L.L.C. The sponsor had no role in study design and concept, analysis and interpretation of data, or manuscript preparation. The publication of results was not contingent on sponsor approval of the manuscript. The authors gratefully acknowledge Rick deFriesse, M.Ed., for assistance with SAS programming.
Dr. Sikirica, Ms. Crivera, and Dr. Dirani are employees of the sponsor, Ortho-McNeil Janssen Scientific Affairs, L.L.C. The other authors report no competing interests.
1.Schizophrenia. NIH pub no 06-3517. Bethesda, Md, US Department of Health and Human Services. National Institutes of Health, 20062.Long-acting injectable antipsychotics: a useful and well tolerated option in elderly patients with psychotic illnesses. Drugs and Therapy Perspectives 20:7—10, 20043.Perkins D: Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry 63:1121—1128, 20064.Liu-Seifert H, Adams DH, Kinon BJ: Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 3:21, 20055.Gilmer TP, Dolder CR, Larco J, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161:692—699, 20046.Ereshefsky L, Mannaert E: Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs in R&D 6:129—137, 20057.Svarstad BL, Shireman TI, Sweeney JK: Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services 52:805—811, 20018.Valenstein M, Copeland LA, Blow FC, et al: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40:630—639, 20029.Gianfrancesco F, Rajagopalan KS, Sajatovic M, et al: Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Research 144:177—189, 200610.Becker MA, Young MS, Ochshom E, et al: The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Administration and Policy in Mental Health 34:307—314, 200711.Valenstein M, Blow FC, Copeland LA, et al: Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin 30:255—264, 200412.Keith SJ, Pani L, Nick B, et al: Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatric Services 55:997—1005, 200413.Weiden PJ, Kozma C, Grogg A, et al: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services 55:886—891, 200414.Love RC: Strategies for increasing treatment compliance: the role of long-acting antipsychotics. American Journal of Health-System Pharmacy 59(22 suppl 8):S10—S15, 200215.McEvoy JP: Risks versus benefits of different types of long-acting injectable antipsychotics. Journal of Clinical Psychiatry 67:15—18, 200616.Keks NA, Ingham M, Khan A, et al: Long-acting injectable risperidone v olanzapine tablets for schizophrenia or schizoaffective disorder: a randomised, controlled, open-label study. British Journal of Psychiatry 191:131—139, 200717.Olfson M, Marcus SC, Ascher-Svanum H: Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophrenia Bulletin 33:1379—1387, 200718.Kane JM, Eerdekens M, Lindenmayer JP, et al: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 160:1125—1132, 200319.Ascher-Svanum H, Zhu B, Faries D, et al: A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. Journal of Clinical Psychiatry 67:1114—1123, 200720.Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology 45:613—619, 199221.Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 40:373—383, 198722.Shi L, Ascher-Svanum H, Zhu B, et al: Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services 58:482—488, 200723.Martin BC, Miller LS: Expenditures for treating schizophrenia: a population-based study of Georgia Medicaid recipients. Schizophrenia Bulletin 24:479—488, 199824.Coldham EL, Addington J, Addington D: Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 106:286—290, 200225.Menzin J, Boulanger L, Friedman M, et al: Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatric Services 54:719—723, 2003
Adjusted odds of medication nonadherence associated with characteristics of patients with schizophrenic disorders treated with antipsychotic medications
Adjusted odds of psychiatric hospitalization associated with characteristics of patients with schizophrenic disorders treated with antipsychotic medications
Adjusted odds of all-cause hospitalization associated with characteristics of patients with schizophrenic disorders treated with antipsychotic medications